NYSE:OSTX OS Therapies (OSTX) Stock Price, News & Analysis $1.73 -0.02 (-1.14%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.72 -0.01 (-0.52%) As of 08/8/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About OS Therapies Stock (NYSE:OSTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OS Therapies alerts:Sign Up Key Stats Today's Range$1.68▼$1.7950-Day Range$1.56▼$1.9852-Week Range$1.12▼$7.00Volume404,504 shsAverage Volume738,270 shsMarket Capitalization$48.61 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. Read More OS Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreOSTX MarketRank™: OS Therapies scored higher than 48% of companies evaluated by MarketBeat, and ranked 624th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingOS Therapies has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOS Therapies has only been the subject of 1 research reports in the past 90 days.Read more about OS Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OS Therapies are expected to grow in the coming year, from ($0.64) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OS Therapies is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OS Therapies is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OSTX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOS Therapies does not currently pay a dividend.Dividend GrowthOS Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OSTX. News and Social Media2.9 / 5News Sentiment0.20 News SentimentOS Therapies has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for OS Therapies this week, compared to 2 articles on an average week.Search Interest18 people have searched for OSTX on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows11 people have added OS Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OS Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of OS Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about OS Therapies' insider trading history. Receive OSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OS Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address OSTX Stock News HeadlinesOS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...1 hour ago | finance.yahoo.comOS Therapies files to sell 3.76M shares of common stock for holdersAugust 6 at 5:28 AM | msn.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Contrasting OS Therapies (NYSE:OSTX) and Nuvo Pharmaceuticals (OTCMKTS:MRVFF)July 31, 2025 | americanbankingnews.comOS Therapies Inc News (OSTX) - Investing.comJuly 18, 2025 | investing.comOS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer TherapyJuly 14, 2025 | theglobeandmail.comOS Therapies Raises $4.2M Through Warrant ExerciseJuly 14, 2025 | tipranks.comOS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy RatingJuly 11, 2025 | tipranks.comSee More Headlines OSTX Stock Analysis - Frequently Asked Questions How have OSTX shares performed this year? OS Therapies' stock was trading at $4.28 on January 1st, 2025. Since then, OSTX stock has decreased by 59.6% and is now trading at $1.73. When did OS Therapies IPO? OS Therapies (OSTX) raised $8 million in an initial public offering on Thursday, August 1st 2024. The company issued 2,000,000 shares at a price of $4.00 per share. Brookline Capital Markets (Division of Arcadia Securities LLC) acted as the underwriter for the IPO. How do I buy shares of OS Therapies? Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OS Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include AST SpaceMobile (ASTS), Energy Transfer (ET), Black Stone Minerals (BSM), Kinder Morgan (KMI), Main Street Capital (MAIN), Atlas Energy Solutions (AESI) and Chevron (CVX). Company Calendar Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:OSTX Previous SymbolNYSE:OSTX CIK1795091 WebN/A Phone(410) 297-7793FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for OS Therapies$18.00 High Price Target$20.00 Low Price Target$15.00 Potential Upside/Downside+940.5%Consensus RatingBuy Rating Score (0-4)3.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.79 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-569.57% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares28,098,000Free FloatN/AMarket Cap$48.61 million OptionableN/A BetaN/A Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:OSTX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.